Prognostic value of MRD in CLL patients with comorbidities receiving chlorambucil plus obinutuzumab or rituximab

Ton Langerak, M Ritgen, V Goede, S Robrecht, J Bahlo, K Fischer, M Steurer, M Trneny, SP Mulligan, UJM Mey, K Trunzer, G Fingerle-Rowson, K Humphrey, S Stilgenbauer, S Bottcher, M Bruggemann, M Hallek, M Kneba, Jacques Dongen

Research output: Contribution to journalArticleAcademicpeer-review

31 Citations (Scopus)
Original languageUndefined/Unknown
Pages (from-to)494-497
Number of pages4
Issue number5
Publication statusPublished - 2019

Research programs

  • EMC MM-02-72-01

Cite this